Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
PR Newswire
INDIANAPOLIS, May 31, 2026
View original content to download multimedia:https://www.prnewswire.com/news-releases/lillys-retevmo-selpercatinib-demonstrated-an-83-reduction-in-the-risk-of-disease-recurrence-or-death-as-adjuvant-therapy-for-people-with-early-stage-ret-fusion-positive-lung-cancer-302786427.htmlSOURCE Eli Lilly and Company
